Investing.com - Crispr Therapeutics (NASDAQ: CRSP) reported second quarter EPS of $-2.40, $1.00 worse than the analyst estimate of $-1.40. Revenue for the quarter came in at $890K versus the consensus estimate of $5.81M.
Crispr Therapeutics’s stock price closed at $59.60. It is up 64.91% in the last 3 months and up 20.02% in the last 12 months.
Crispr Therapeutics saw 6 positive EPS revisions and 11 negative EPS revisions in the last 90 days. See Crispr Therapeutics’s stock price’s past reactions to earnings here.
According to InvestingPro, Crispr Therapeutics’s Financial Health score is "fair performance".
Check out Crispr Therapeutics’s recent earnings performance, and Crispr Therapeutics’s financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar
ProPicks AI evaluates CRSP alongside thousands of other companies every month using 100+ financial metrics. Using powerful AI to generate exciting stock ideas, it looks beyond popularity to assess fundamentals, momentum, and valuation. The AI has no bias—it simply identifies which stocks offer the best risk-reward based on current data with notable past winners that include Super Micro Computer (+185%) and AppLovin (+157%). Want to know if CRSP is currently featured in any ProPicks AI strategies, or if there are better opportunities in the same space?